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Abstract
Background: To clarify the effect of human umbilical cord-derived mesenchymal stem cell (hUC-MSCs) treatment
on colitis and to explore the role of CD5+ B cells in MSC therapy.
Methods: The trinitrobenzenesulfonic acid (TNBS)-induced colitis mouse model was used. HUC-MSCs were transferred
peritoneally. Survival rates, colitis symptoms, and macroscopic and histologic scores were evaluated. CD4+ T helper (Th)
cell subgroups and CD5+ regulatory B cell (Bregs) in lymphocytes were quantitated by flow cytometry. Cytokine levels
were detected by ELISA and Bio-plex. CD5+ B cells were isolated for in vitro co-culture and adaptive transfer.
Results: HUC-MSC treatment alleviated TNBS-induced colitis by increasing survival rates, relieving symptoms,
and improving macroscopic and histologic scores. Labeled hUC-MSCs were located in the inflamed areas of
colitis mice. Increases in regulatory T cells (Tregs) and CD5+ B cells and decreases in Th1 cells, Th17 cells, and
several pro-inflammatory cytokines were observed with hUC-MSC treatment. After adaptive transfer, CD5+ B
cells, which were located mainly in the peritoneal lavage fluid, improved TNBS-induced colitis by correcting
Treg/Th1/Th17 imbalances. CD5+ B cells also inhibited T-cell proliferation and produced interleukin (IL)-10.
Conclusions: HUC-MSCs protected against experimental colitis by boosting the numbers of CD5+ B cells and
IL-10-producing CD5+ Bregs, and correcting Treg/Th17/Th1 imbalances.
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Background
Crohn’s disease (CD) is a chronic, recurrent inflammatory
disease of the gastrointestinal tract and is characterized by
T-cell dysfunction, altered cytokine production, and cellu-
lar inflammation. These factors ultimately lead to mucosal
damage of the alimentary tract. Although the etiology
of CD remains unknown, there is substantial evidence
showing that a failure of the mucosal immune system
plays a key role in CD, especially the imbalance between
effector T cells and suppressive regulatory T cells (Tregs).
This imbalance results in the expansion of self-reactive T
cells and inflammation [1]. Therefore, many available ther-
apies and new drugs on the pipeline target inflammation-
associated pathways. However, these therapies are not
effective enough, as they are mostly nonspecific and can
cause multiple adverse effects. This illustrates the need for
novel therapeutic approaches and specific therapies that
focus on immune regulation. The restoration of immune
tolerance by the re-establishment of Treg/T helper (Th)
cells imbalances has been proposed as an attractive
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therapeutic approach for CD. Stem cell therapy for CD
has attracted attention since 1993, when the first case re-
port of stem cell therapy in a CD patient was published
[2]. Many case series and pilot clinical trials have demon-
strated the efficacy of stem cell therapy, but with much
uncertainty [3].
Mesenchymal stem cells (MSCs) are mesoderm-derived,
fibroblast-like somatic cells that reside in the stroma of
solid organs and function as precursors of nonhemato-
poietic connective tissues [4]. Recent studies have shown
that MSCs are effective and safe in clinical trials of
various pathologies, including graft-versus-host diseases
(GVHD), rheumatic diseases, and inflammatory bowel
diseases [5–8]. The mechanisms involved in these trials
included the inhibition of T-cell proliferation, B-cell
function, and dendritic cell maturation via the secretion
of soluble factors by MSCs [9]. Apart from bone
marrow-derived MSCs (BM-MSCs), which are the most
widely used MSCs, other major sources of human
MSCs are the umbilical cord, peripheral blood, and adi-
pose tissue. Due to difficulties in obtaining sufficient
autologous BM-MSCs, human MSCs obtained from the
umbilical cord (hUC-MSCs) have recently emerged as
an attractive alternative for cell therapy. In addition to
its “immune-privileged” status and immunomodulatory
properties, hUC-MSCs are easier to collect and expand
in vitro [10, 11], thus making it a potentially promising
tool in clinical applications.
Previous studies have focused on the effect of MSCs on
T cells; however, recent studies found that a new regula-
tory subset, B regulatory cells (Bregs), could also play an
important role. For example, a recent study focusing on
an animal model of experimental autoimmune encephalo-
myelitis (EAE) found that the number of CD5+ Bregs
increased after MSC therapy [12]. Our recent study
involving BM-MSCs for GVHD patients also showed this
phenomenon [13]. Therefore, we conducted this study to
clarify the effect of hUC-MSCs on the treatment of
experimental colitis in mice and to also explore the role of
CD5+ B cells in hUC-MSC therapy.
Methods
Cell preparation
Human umbilical cords from full-term Caesarean section
patients were collected upon delivery, stored in Dulbecco’s
modified Eagle medium (DMEM)/F12 (1:1) culture me-
dium, which was supplemented with 100 U/ml penicillin
and 100 μg/ml streptomycin (GIBCO, Invitrogen Inc.,
Carlsbad, CA, USA), and transferred immediately for cell
isolation, according to a previously described protocol
[14]. Briefly, the cord was cut into pieces that were 4–5
cm long, and the vessels were pulled away to isolate
Wharton’s Jelly (WJ). WJ was cut into 1–2-mm3 pieces
and digested with 1 mg/ml collagenase II (Millipore
Sigma, St. Louis, MO, USA) with phosphate-buffered sa-
line (PBS) at 37 °C for 45 min. The digested mixture was
then passed through a 100-μm filter (BD Biosciences,
Franklin Lakes, NJ, USA) to obtain cell suspensions. The
cells were washed with PBS solution and then cultured in
DMEM/F12 medium containing 10 % fetal bovine serum,
2 mmol/L glutamine, 1 % nonessential amino acids,
and 1 % penicillin/streptomycin (GIBCO, Invitrogen
Inc., Carlsbad, CA, USA) at 37 °C and 5 % CO2. Nonad-
herent cells were removed by changing the medium
after 3 days. Cells were expanded and identified according
to the current statement of the International Society for
Cellular Therapy (ISCT) [15]. Briefly, a minimal set of
three standard criteria was used as the uniform definition
of multipotent MSCs: adherence to plastic, specific surface
antigen expression, and multipotent differentiation poten-
tial. The phenotype of multipotent MSCs is defined to be,
at a minimum, the cell surface co-expression of antigens
(CD105, CD73, and CD90 [≥95 % positive]) and the ab-
sence of hematopoietic lineage markers (CD45, CD34,
CD14, CD19, and HLA-DR [≤2 % positive]). The surface
marker was defined by the BD Stemflow hMSC Analysis
Kit (BD Biosciences, Franklin Lakes, NJ, USA) containing
pre-conjugated and pre-titrated cocktails of ISCT-defined
positive expression markers (CD105 PerCP-Cy™5.5/CD73
APC/CD90 FITC) and negative expression markers
(CD45/CD34/CD11b/CD19/HLA-DR PE). The multipo-
tent differentiation potential of the isolated cells was
identified using the Human Mesenchymal Stem Cell
Functional Identification Kit (R&D, Minneapolis, MN,
USA). Briefly, hUC-MSCs were seeded at 2 × 104 cells/cm2
in StemXVivo Osteogenic/Adipogenic Base Media. And
after 24 hours, the medium was replaced with adipo-
genic differentiation medium to induce adipogenesis.
HUC-MSCs were seeded at 4.2 × 103 cells/cm2 in
StemXVivo Osteogenic/Adipogenic Base Media. When
cells were to 50–70 % confluency, the medium was re-
placed by osteogenic differentiation medium. Differen-
tiation medium was replaced every 3 days, and after 3
weeks cells were fixed in 10 % formalin and processed
for histochemical analysis. Adipogenic differentiation
was detected by oil red staining, and osteogenic differenti-
ation was analyzed by alizarin red staining. This project
was approved by the Human Ethics Committee of The
First Affiliated Hospital at Sun Yat-sen University, and
written informed consent was obtained for umbilical cord
collections.
Induction of colitis and cell transplantation
Colitis was induced in specific pathogen-free male
BALB/c mice (6–8 weeks old), according to a previously
described method [16]. All experiments were performed
according to the Institutional Guidelines for the Care
and Use of Laboratory Animals in Research and were
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approved by the Ethics Committee at Sun Yat-sen Univer-
sity. Briefly, mice were pre-sensitized with the trinitroben-
zenesulfonic acid (TNBS) pre-sensitization solution on day
1. The pre-sensitization solution was prepared by mixing
acetone and olive oil in a 4:1 volume ratio by rigorous vor-
texing and then mixing 4 volumes of acetone/olive oil with
1 volume of 5 % TNBS solution to obtain 1 % (w/v) TNBS.
Control mice were treated with the pre-sensitization solu-
tion without TNBS. BALB/c mice were lightly anesthetized
after a 24-hour fast on day 8. To induce colitis, 5 %
TNBS (Millipore Sigma, St. Louis, MO) in 50 % etha-
nol (2.5 mg/kg TNBS) was administered intrarectally via a
3.5 French (F) catheter equipped with a 1-ml syringe. The
catheter was inserted into the rectum until the tip was ad-
vanced to 4 cm proximal to the anal verge. Control mice
received 50 % ethanol alone. Passages 3–5 of hUC-MSCs
were used for cell transplantation. BALB/c mice were
treated intraperitoneally either with the medium as the
control or with 106 hUC-MSCs/mouse 2 hours after instil-
lation of TNBS.
Assessment of colitis severity
Animals were monitored for the appearance of diarrhea,
body weight loss, and survival every day for a total of 14
days. The baseline data were collected before instillation of
TNBS. Disease activity and histologic scores were evalu-
ated as previously described [17]. For disease activity, a
score system containing percentage of weight loss, stool
consistency, and fecal occult blood test was used [16, 17].
For histopathology analysis, a colon specimen from the
middle part (1 cm to the anus to cecum) was fixed in 10 %
buffered formalin phosphate and then embedded in paraf-
fin. Sections were stained with hematoxylin and eosin, and
inflammation was graded from 0–4 as follows, in a blinded
fashion: 0, no signs of inflammation; 1, low leukocyte infil-
tration; 2, moderate leukocyte infiltration; 3, high leukocyte
infiltration, moderate fibrosis, high vascular density, thick-
ening of the colon wall, moderate goblet cell loss and focal
loss of crypts; and 4, transmural infiltrations, massive loss
of goblet cells, extensive fibrosis, and diffuse loss of crypts.
Myeloperoxidase (MPO) activity was assessed by the MPO
kit (Jiancheng, Nanjing, China), according to the manufac-
turer’s instructions. For survival and colitis score analysis,
there were 20 mice in the model and treatment groups and
10 mice for the control and naïve groups. For histological
and immunological analysis, mice were sacrificed at day 3
after colitis induction, at the peak of inflammation (n = 9
for each group).
In vivo imaging
MSCs were traced in vivo with the Renilla Luciferase Assay
System (Promega, Madison, WI, USA). First, the EGFP-
luciferase system was conducted and transferred to MSCs.
Cell transplantation was conducted as described above.
Renilla luciferase substrate was intraperitoneally injected
after cell transfer at different time points (day 1, day 3,
and day 5). Using the Xenogen IVIS Spectrum in vivo vis-
ible light system (Caliper Life Sciences, Hopkinton, MA,
USA), cell tracing was performed at about 10 min after
substrate injection.
Immunologic analysis of T- and B-cell subsets in the
mesenteric lymph node (MLN) and spleen
Colitis mice were sacrificed at day 3 after colitis induc-
tion, at the peak of inflammation. Lymphocytes of MLN
cells and the spleen were isolated through a 100-μm
filter (BD Biosciences, Franklin Lakes, NJ, USA). Lym-
phocytes were then suspended at a density of 2 × 106
cells/ml in RPMI 1640 culture medium, which was sup-
plemented with 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 2 mmol/L glutamine, and 10 % heat-inactivated
fetal calf serum (GIBCO, Invitrogen Inc., Carlsbad, CA,
USA). To identify Tregs, 2 × 106 lymphocytes were
surface-labeled with phycoerythrin (PE)-labeled anti-
CD4 and allophycocyanin (APC)-cyanine (Cy)7-labeled
Foxp3. For Th1/Th2/Th17 cell subgroup analyses, 2 ×
106 cells were stimulated with 50 ng/ml phorbol myris-
tate acetate and 1 mmol/L ionomycin (Millipore Sigma,
St. Louis, MO, USA) for 4 hours in the presence of
monensin (BD Biosciences, Franklin Lakes, NJ, USA).
The incubator was set at 37 °C under a 5 % CO2 at-
mosphere. After 4 hours, intracellular staining was
performed with APC-labeled anti-CD4, PE-labeled
anti-interleukin (IL)-4, PE-labeled anti-IL-17, and
FITC-labeled anti-interferon (IFN)-γ (BD Biosciences,
Franklin Lakes, NJ, USA). For CD5 cell subgroup ana-
lysis, cells were surface-labeled with FITC-labeled CD5
and PE-CY7-labeled CD19. Flow cytometry was carried
out using a BD FACScan (BD Biosciences, Franklin Lakes,
NJ, USA), in which 300,000–500,000 events were col-
lected, and lymphocytes were gated based on their for-
ward and side light scatter properties. Data were analyzed
using the Gallios Flow Cytometer (Beckman Coulter, Brea,
CA, USA) and Kaluza Analysis software. The propor-
tion of Tregs was determined based on CD4+Foxp3.
CD4+IFN-γ+, CD4+IL-4+, CD4+IL-17+, and CD5 +
CD19+ cells were defined as Th1 cells, Th2 cells,
Th17 cells, and CD5+ Bregs, respectively. For cytokine
expression, the serum was separated from peripheral
blood collected through tail vein on day 3. Tumor ne-
crosis factor (TNF)-α, IL-12, IL-6, IL-23, IL-21, IFN-γ,
and IL-17A were detected by the ProcartaPlex™ Multi-
plex Immunoassays kit (eBioscience, Santa Clara, CA,
USA) and Bio-plex system (Bio-Rad, Hercules, CA,
USA). Transforming growth factor (TGF)-β was
detected by measured by an enzyme-linked immuno-
sorbent assay (ELISA) (eBioscience, Santa Clara, CA,
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USA), according to manufacturer instructions. All as-
says were performed in triplicate wells per condition in
each experiment.
In vitro and in vivo study of CD5+ Bregs
CD5+ B cells have been shown to exist in the peritoneal
cavity [18]. Thus, CD5+ B cells were also analyzed in
peritoneal lavage fluid to clarify its distribution in hUC-
MSC-treated colitis mice. CD5+ B cells were isolated by
flow cytometry and co-cultured with carboxyfluorescein
succinimidyl ester (CFSE) (Invitrogen, Inc., Carlsbad,
CA, USA)-labeled T cells. Cell proliferation was then de-
tected by flow cytometry (Beckman Coulter, Brea, CA,
USA). For the in vivo functional study, CD5+ B cells were
isolated form spleen lymphocytes by flow cytometry. Iso-
lated CD5+ B cells were transplanted through the tail vein
of TNBS-induced colitis mice on day 3, in the peak of the
inflammation. Disease severity and T-cell subgroups were
analyzed according to the methods described above.
Results
Identification of hUC-MSCs
The hUC-MSCs showed a fibroblast-like morphology,
expressed certain antigens (CD105, CD73, and CD90
[≥95 % positive]), and lacked hematopoietic lineage
markers (CD45, CD34, CD14, CD19, and HLA-DR [≤2 %
positive]). After certain inducing environments of osteo-
genesis and adiposis, the cells had the ability to differ-
entiate multidirectionally to osteogenesis and adiposis
(Additional file 1: Figure S1).
HUC-MSC therapy protected against TNBS-induced colitis
TNBS-treated mice developed a severe illness, which
was characterized by bloody diarrhea, rectal prolapse,
pancolitis, and sustained weight loss. The mortality of
the colitis model was 55 %, whereas the rates were 20 %
in hUC-MSC-treated TNBS mice and 0 % in ethanol
and naïve controls (Fig. 1a). Similar to ethanol control
mice, hUC-MSC-treated mice had rapidly recovered
body weight loss (b-c) and milder inflammation. They
also exhibited significantly lower colitis, decreased
macroscopic and histologic scores (Fig. 1d–f ), and less
neutrophil infiltration, as reflected by lower MPO activity
(Fig. 1g). Macroscopic examination of TNBS colons
showed hyperemia, edema, and inflammation that were
significantly more severe than that in HUC-MSC-treated
mice (Fig. 1h, j). Histologic examination of the colons
showed that HUC-MSC treatment reduced the TNBS-
induced inflammation of the transmural area, depletion of
epithelial cells, and focal loss of crypts (Fig. 1i).
HUC-MSCs may migrate to the inflamed areas
By in vivo cell tracing, we found that hUC-MSCs accu-
mulated in the peritoneal cavity of TNBS and ethanol
mice on day 1 (6 hours after colitis induction), whereas
only a few cells that were limited to the site of cell injec-
tion could be found in naïve mice. At the peak of colitis,
the cells still accumulated in the abdomen of TNBS mice
but could not be detected in ethanol and naïve mice,
thus suggesting relevance with colon inflammation. At
day 5, when recovery from colitis began, the number of
hUC-MSCs gradually decreased and could not be traced
(Fig. 2). This phenomenon indicated that the MSCs may
migrate to the inflamed area and be associated with the
degree of inflammation.
HUC-MSCs altered Th cell and Treg imbalance in
colitis mice
We further used flow cytometry to analyze immunologic
changes after hUC-MSC transplantation. In splenic
lymphocytes, the Treg proportions were 4.31 ± 0.21 %,
1.77 ± 0.32 %, 3.49 ± 1.20 %, and 5.05 ± 0.23 % in hUC-
MSC-treated mice, TNBS mice, ethanol control mice,
and naïve mice, respectively. Similar tendencies in
MLN lymphocytes were observed among groups (Fig. 3).
Furthermore, there was a significant decrease in Th1
and Th17 cells in both splenic and MLN lymphocytes
after hUC-MSC therapy (Fig. 4). Th2 cells were rarely
expressed, and no differences were observed after cell
transfer. Levels of pro-inflammatory cytokines, such as
TNF-α, IL-12, IL-6, IL-23, and IL-21, decreased signifi-
cantly in the plasma after MSC treatment (P < 0.05). IL-
17A, which is the main cytokine of Th17 cells, showed a
decreased tendency (P = 0.09) (Fig. 5). IL-10 and TGF-β,
which are associated with immunosuppression, were sig-
nificantly higher in hUC-MSC-treated mice (P = 0.04 and
0.02, respectively).
CD5+ B cells alleviated colitis in mice in vivo by
regulating T-cell responses
We found a significant increase in CD5+ B cells after cell
transplantation in both splenic and MLN lymphocytes
(Fig. 6), suggesting that CD5+ B cells might play a role
in immune regulation. Interestingly, CD5+ B cells mainly
distributed in the peritoneal cavity and decreased signifi-
cantly in the colitis model; this was reversed by hUC-
MSC therapy (Fig. 6). The above phenomenon led us to
hypothesize that CD5+ B cells could regulate T-cell
imbalance.
To further clarify the function of CD5+ B cells, we
conducted both in vivo and in vitro studies. Adaptive
transfer of isolated CD5+ B cells had the same effect as
hUC-MSC therapy (Fig. 7) and resulted in increased sur-
vival, decreased disease activity, and lower macroscopic
and histologic scores. Interestingly, this effect was asso-
ciated with an alteration of Th/Treg balances (Fig. 7).
The in vitro co-culture of hUC-MSCs and splenic lym-
phocytes significantly increased the number of CD5+ B
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cells (Fig. 8). When co-cultured with CFSE-labeled T
cells, CD5+ B cells could inhibit T-cell proliferation and
may be associated with IL-10 (Fig. 8).
Discussion
In the past decades, new drugs for CD have greatly im-
proved the efficacy and quality of life of CD patients.
However, even in the era of biologics, the fight against
CD is far from over, as there is still no ideal treatment
or cure. Findings from recent studies have confirmed that
immunologic factors play a central role in the pathogen-
esis of CD. We have previously found imbalances among
CD4+ T-cell subgroups in Chinese CD patients. Treg/Th1
and Treg/Th17 ratios are associated with disease activity
and are potential prognostic indicators for predicting CD
recurrence [19]. Thus, new treatments targeting immune
Fig. 1 Human umbilical cord-derived mesenchymal stem cell (hUC-MSC) therapy protects against TNBS-induced colitis. HUC-MSC therapy increased
the survival rate of experimental colitis mice (a), decreased weight loss (b and c), alleviated colitis symptoms (d), and improved macroscopic (e) and
histologic (f) scores. Myeloperoxidase (MPO) activity is shown in (g), and pictures of the colon (h) with hematoxylin and eosin staining (i) of each group
are presented. The colon length which can reflect the inflammation was shown in (j). n = 20 for colitis model and treatment groups; n = 10 for model
control and naïve mice; *P < 0.05 vs. MSC-treated mice. TNBS trinitrobenzenesulfonic acid
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Fig. 3 hUC-MSCs alter numbers of regulatory T cells (Tregs) in colitis mice. Lymphocytes were co-stained with anti-CD4 and anti-FoxP3 antibodies
and evaluated by flow cytometry. Tregs were defined as CD4+FoxP3+. The frequency of Tregs from the hUC-MSC-treated group was significantly lower
than that in controls. Representative dot plots of Tregs in the spleen (a) and mesenteric lymph node (MLN) (c) of each group. Treg proportions are shown
in (b) and (d). Data are presented as plots with P value. n= 9 for each group; *P< 0.05 vs. MSC-treated mice. hUC-MSC human umbilical cord-derived
mesenchymal stem cell, TNBS trinitrobenzenesulfonic acid
Fig. 2 MSCs migrate to the inflamed areas. In vivo tracing of MSCs on days 1, 3, and 5, the labeled cells were detected by the imaging system.
Warmer colors indicate more accumulation of cells. MSCs mesenchymal stem cells, TNBS trinitrobenzenesulfonic acid
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imbalances over specific cytokines appear to be the best
therapeutic candidates for CD.
MSC therapy has been promising in several inflamma-
tory diseases, including CD. Th1 and Treg imbalances
play a central role [8, 17, 20–24] in CD. However, up to
now, there has only been one report concerning the
effect of hUC-MSCs on experimental colitis. This report
showed that hUC-MSCSs could modulate Treg/Th1/Th17
imbalances [14]. Similarly, we showed that hUC-MSCs in-
deed alleviated experimental colitis. We also confirmed an
Fig. 4 hUC-MSCs alter T helper cell subgroups in colitis mice. Populations of Th1/Th2/Th17 cells as a proportion of total CD4+ cells were
evaluated by flow cytometry. Cells were co-stained with antibodies against CD3, CD8, interferon (IFN)-γ, interleukin (IL)-4, or IL-17 (CD4+ cells).
CD3+CD8- cells were gated (a). CD4+IFN-γ+, CD4+IL-4+, and CD4+IL-17+ cells were defined as Th1, Th2, and Th17 cells, respectively. Representative
dot plots are shown in panels b–c. Proportions of Th1 and Th17 cells in the four participant groups are shown in panels d–g. Data are presented
as plots with P value. n = 9 for each group; *P < 0.05 vs. MSC-treated mice. hUC-MSC human umbilical cord-derived mesenchymal stem cell, TNBS
trinitrobenzenesulfonic acid
Fig. 5 Serum cytokine expression in each group. Th1 cell-related cytokines (tumor necrosis factor [TNF]-α and interleukin [IL]-12) and Th17 cell-related
cytokines (IL-6, IL-23, and IL-21) were decreased after cell transplantation. IL-10 and transforming growth factor (TGF)-β were increased
after cell transplantation. For IL-17A, there was a decreased tendency (P = 0.09). n = 6 for each group; *P < 0.05 vs. TNBS-treated mice. hUC-MSC human
umbilical cord-derived mesenchymal stem cell, TNBS trinitrobenzenesulfonic acid
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alteration of Treg/Th1/Th17 imbalances and cytokine pro-
duction after cell transplantation. Strikingly, the number of
CD5+ B cells increased significantly after hUC-MSC ther-
apy. In previous studies, Bregs showed an immunosuppres-
sive role via the expression of CD5 and secretion of IL-10
[25–29]. Although there are controversies concerning the
definition and surface marker of Bregs, this subset is known
to exert immunosuppressive functions by regulating Th
cells and Tregs, inducing T-cell and B-cell apoptosis, and
inhibiting other immune-related cells, including CD8+ T
cells and natural killer T cells. Furthermore, Bregs are asso-
ciated with autoimmune diseases, such as type I diabetes,
GVHD, arthritis, and lupus [29, 30]. In colitis models, Bregs
can exert anti-inflammatory effects [27, 28, 31]. In a T-cell
receptor-α-/- colitis model, B-cell depletion resulted in
severe colitis, whereas the adaptive transfer of B cells allevi-
ated the colitis symptoms. When CD1d was simultaneously
knocked out, the symptoms of colitis became more severe,
thereby suggesting that the B-cell subset can regulate
inflammation in the colitis models [27]. In IL-10-/- experi-
mental colitis models, IL-10-expressing B cells alleviate
colitis [28]. Only two studies have reported increases in the
numbers of CD5+ B cells after BM-MSC transplantation.
One study involved the EAE model and revealed an in-
crease in numbers of CD5+ B cells after BM-MSC trans-
plantation [12], however, this study did not further analyze
the potential mechanisms and function of CD5 + B cells.
The other study from our team revealed that the CD5+ B
subset is associated with the efficiency of BM-MSC therapy
in GVHD [13]. In the present study, in vivo cell tracing re-
sults show that the cells exerted their function specifically
in the inflamed areas. As CD5+ B cells mainly reside in the
peritoneum, we analyzed the proportion of CD5+ B cells in
peritoneal lavage fluid, splenic lymphocytes, and MLN lym-
phocytes. Numbers of CD5+ B cells were significantly ele-
vated after hUC-MSC transfer. We also conducted further
in vivo and in vitro studies to verify whether MSCs can
regulate CD5+ B cells to modulate the immune status of
Fig. 6 CD5+ B cells significantly increase after hUC-MSC therapy. Populations of CD5+ B cells were identified as CD5+CD19+ by flow cytometry.
Representative dot plots of CD5+ B cells in the spleen (a), mesenteric lymph node (MLN) (c), and peritoneal cavity (e) are shown. Data are presented as
plots with P value (b, d and f). n = 9 for each group; *P < 0.05 vs. MSC-treated mice. hUC-MSC human umbilical cord-derived mesenchymal stem cell,
TNBS trinitrobenzenesulfonic acid
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the colitis model. Upon co-culture with hUC-MSCs, CD5+
B cells increased and inhibited T-cell proliferation in vitro.
In addition, the adaptive transfer of CD5+ B cells into colitis
mice alleviated colitis in a similar manner as that achieved
with hUC-MSCs. Importantly, this effect was associated
with the alteration of Th/Treg imbalances. CD5+ Bregs also
inhibited T-cell proliferation in vitro. These findings suggest
that CD5+ B cells can exert a regulatory effect and protect
against TNBS-induced colitis by regulating T-cell balances.
Therefore, the effect of CD5+ B cells may be a new mech-
anism of MSC therapy in CD. Furthermore, CD5+ B cells
produced more IL-10 mRNA and protein, thus indicating
that IL-10 may be an important factor that coordinates the
immunoregulatory effect of MSC-induced Bregs. It should
be emphasized that CD5 is also highly expressed on
B-cell chronic lymphocytic leukemia (B-CLL). The
specific surface marker ROR1 [32] and receptor of
lysophosphatidic acid (LPA) [33, 34] are the markers
of B-CLL but not normal B cell. To differentiate the
immunosuppressive B cells form B-CLL, we isolated
the CD5+B cell from naïve, model and MSC-treated
mice and detected the expressions of LPA receptors
(LPARs) by real-time PCR. We found a very low ex-
pression of LPARs (LPAR1-5) genes. Furthermore, the
expressions of LPARs in naïve, model and MSC-
treated mice were similar. Therefore, we concluded
that the increased CD5 + B cell after MSCs trans-
plantation were normal B cells.
We did in vivo cell tracking using the luciferase
reporting system. We found that direct cell repair may
be less important than immune regulation, as the cells
could not be detected 5 days after cell transplantation.
Interestingly, the cells mainly distributed in the abdo-
men when transferred peritoneally in the colitis model,
while they could not be tracked in naïve mice. One pos-
sible reason is that the cells distributed to a wide range
of tissues and organs in a random fashion in naïve
mice, as shown in previous studies [14, 35]. But the
IVIS system can track the cells when the signal is large
enough where cells were aggregated together. However,
we knew very little about the destination of the cells in
our analysis. Therefore, a more specific three-dimensional
option with high resolution was needed to further localize
the cells in vivo.
Fig. 7 Adaptive transfer of CD5+ B cells alleviates TNBS-induced colitis. Sorted CD5+ B cells (a) were used for transplantation. After adaptive
transfer, the cells showed similar efficiency in colitis mice as hUC-MSCs (b–e), and this effect was associated with Treg/Th imbalances (f–i).
hUC-MSC human umbilical cord-derived mesenchymal stem cell, MLN mesenteric lymph node, Th T helper, TNBS trinitrobenzenesulfonic acid
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This study has some limitations. First, we used the
surface marker CD5+ to define Bregs and did not further
clarify other Breg subsets with different surface markers.
Second, we did not explain the mechanisms of how hUC-
MSCs can induce CD5+ Breg differentiation. Further ana-
lysis is needed to clarify these questions.
Conclusions
We show for the first time that hUC-MSCs could protect
against experimental colitis in mice by correcting Treg/
Th17/Th1 imbalances. The underlying mechanism possibly
acts via boosting the numbers of CD5+ B cells and IL-
10-producing CD5+ Bregs. Further analysis is needed to
clarify the issue that hUC-MSCs can induce CD5+ Breg
differentiation.
Additional file
Additional file 1: Figure S1. Identification of human umbilical cord-
derived mesenchymal stem cells (hUC-MSCs). HUC-MSCs were identified
according to the International Society for Cellular Therapy statement. The
cells were adherent to plastic (A), differentiated to adipocytes (B) and
osteoblasts (C) in vitro, and expressed specific surface antigens (positive
for CD73, CD90, and CD105; negative for CD45, CD34, CD14, CD19, and
HLA-DR) (D). (TIF 6040 kb)
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